ABIN

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australianbiotechnology company Avexa (ASX:AVX) announced today thecompletion of apricitabine's controlled, double blinded phase whichrepresents the first 24 week segment of its Phase IIb trial.Patients have now progressed into the open-label section of thetrial (weeks 24 to 48) and will continue to receive 800mgapricitabine twice a day a...

PromegaExpress Expands Easy Access to Products with New Cabinet

MADISON, Wis.--(BUSINESS WIRE)--Jun 21, 2007 - ThePromegaExpress(TM) on-site stocking program just added a newlysized ambient cabinet to its line of on-site appliances. Thislatest addition serves as great option to meet individual labinventory requirements for smaller areas when space is at a premiumbut immediate access to life science tools is a necessity. Themid-sized cabinet can also be...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

~ Valopicitabine achieved both primary and secondary endpoints ofstudy; no negative drug-drug interaction was observed betweenvalopicitabine and ribavirin ~ CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- IdenixPharmaceuticals, Inc. today announced results from a phase II studydesigned to evaluate triple combination therapy, consisting ofvalopicitabine (NM283), Idenix's lead dru...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

ASCO publication highlights health care cost benefit ofbioengineering paclitaxel CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced that data published in the 2007Annual Meeting of the American Society of Clinical Oncology (ASCO)abstracts showed reduced medical resource utilization (MRU) andassociated costs with XYOTAX (paclitaxel polyglumex) treatment...

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythat it will report results from a Phase I pharmacologic trial ofsapacitabine (CYC682), a novel orally-available nucleoside analog,in patients with advanced leukemias or myelodysplastic syndromes(MDS), at the American Society of Clinical Oncology's (ASCO) Annual...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announces that a poster by Dr. MaureenE. Lane et al. of , New York, entitled "In Vivo Synergy betweenOncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116Xenografts" is scheduled to be presented today at the AmericanAssociation for Cancer Research (AACR) Annual Meeting in LosAngeles, CA. The m...

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combinedwith an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ --Idenix Pharmaceuticals, Inc. today announced results from two phaseIIb studies of the novel combination of valopicitabine (NM283) andpegylated interferon alfa-2a (Pegasys(R)) in both treatment-naiveand treatment- experienced p...

Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2 Study Data in Neurology

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 10, 2007 - ValeantPharmaceuticals International (NYSE:VRX) announced today thepublication of Phase 2 data for retigabine, a first-in-classneuronal potassium channel opener, in Neurology, a leadingindependent, scientific journal. The authors concluded thatretigabine was efficacious with a demonstrated reduction in monthlyseizure rates in this study....

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - CyclacelPharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announcedtoday that scientists from the company will present results of twopreclinical studies with sapacitabine and seliciclib, the company'smost advanced drug candidates in clinical development. The resultswill be reported in two poster presentations during the upcomingAnnu...

Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting

CALGARY, March 13, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. announced today that an abstract covering preclinicalwork using reovirus in combination with gemcitabine is availabletoday on the American Association for Cancer Research (AACR)website at <a target="_blank" href="http://www.aacr.org/">www.aacr.org , and on the Oncolyticswebsite at <a target="_blank" href="http://...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1antagonist rimonabant to show benefits beyond weight reduction andavoid image as life-style drug BARCELONA, Spain | March 08, 2007 | The Business Intelligencefirm La Merie S.L. reported today that Sanofi-Aventis’first-in-class CB1 antagonist Acomplia (rimonabant) has at leastfive competitors in clinical stages up to phase...